Insulet Corporation $PODD Shares Sold by OLD National Bancorp IN

OLD National Bancorp IN lowered its holdings in Insulet Corporation (NASDAQ:PODD) by 16.6% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 734 shares of the medical instruments supplier’s stock after selling 146 shares during the period. OLD National Bancorp IN’s holdings in Insulet were worth $231,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in PODD. Larson Financial Group LLC grew its holdings in shares of Insulet by 426.3% in the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 81 shares in the last quarter. Zions Bancorporation National Association UT acquired a new position in shares of Insulet in the first quarter valued at approximately $26,000. SouthState Corp grew its holdings in Insulet by 253.3% during the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock worth $28,000 after acquiring an additional 76 shares in the last quarter. Kozak & Associates Inc. acquired a new position in Insulet during the 2nd quarter worth approximately $32,000. Finally, Ramirez Asset Management Inc. acquired a new position in Insulet during the 1st quarter worth approximately $53,000.

Analyst Ratings Changes

Several research analysts have commented on PODD shares. Jefferies Financial Group reiterated a “buy” rating on shares of Insulet in a report on Thursday, August 7th. Barclays boosted their price target on shares of Insulet from $266.00 to $300.00 and gave the stock an “equal weight” rating in a report on Thursday, August 21st. Rothschild & Co Redburn boosted their price target on shares of Insulet from $350.00 to $370.00 and gave the stock a “buy” rating in a report on Friday, October 3rd. Piper Sandler boosted their price target on shares of Insulet from $320.00 to $360.00 and gave the stock an “overweight” rating in a report on Tuesday, September 16th. Finally, Royal Bank Of Canada boosted their price target on shares of Insulet from $330.00 to $350.00 and gave the stock an “outperform” rating in a report on Friday, August 8th. Seventeen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, Insulet currently has an average rating of “Moderate Buy” and a consensus target price of $346.83.

Insulet Stock Up 0.7%

PODD stock opened at $315.49 on Thursday. The company has a fifty day moving average price of $322.51 and a 200 day moving average price of $299.51. Insulet Corporation has a 12 month low of $225.37 and a 12 month high of $353.50. The company has a market cap of $22.21 billion, a price-to-earnings ratio of 95.89, a price-to-earnings-growth ratio of 2.60 and a beta of 1.40. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, beating the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. During the same quarter in the prior year, the firm earned $0.55 EPS. Insulet’s revenue for the quarter was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Sell-side analysts expect that Insulet Corporation will post 3.92 earnings per share for the current year.

Insider Buying and Selling at Insulet

In other Insulet news, SVP Prem Singh sold 687 shares of the company’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the transaction, the senior vice president owned 3,456 shares in the company, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Laetitia Cousin sold 797 shares of the company’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the transaction, the senior vice president owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is owned by corporate insiders.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.